HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

1- (2- aminoacetyl)- 4- benzamidopyrrolidine- 2- carboxylic acid

an antiarrhythmia agent; structure in first source

Also Known As:

GAP 134; GAP-134

Networked: 7 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Hennan, James K: 4 articles (09/2009 - 04/2009)
2.	Rossman, Eric I: 4 articles (09/2009 - 04/2009)
3.	Morgan, Gwen A: 3 articles (09/2009 - 06/2009)
4.	Swillo, Robert E: 3 articles (09/2009 - 06/2009)
5.	Butera, John: 2 articles (09/2009 - 06/2009)
6.	Gardell, Stephen J: 2 articles (09/2009 - 06/2009)
7.	Kantrowitz, Joel: 2 articles (09/2009 - 06/2009)
8.	Baró, Isabelle: 1 article (01/2020)
9.	Bihouée, Audrey: 1 article (01/2020)
10.	Carcouët, Agnès: 1 article (01/2020)

Related Diseases

1.	Cardiomyopathies (Cardiomyopathy) 04/01/2009 - "The present study assessed the effect of the gap junction conduction-enhancing antiarrhythmic peptide GAP-134 on AF inducibility and maintenance in a dog model of atrial cardiomyopathy. "
2.	Fibrosis (Cirrhosis) 01/01/2020 - "Finally, our study suggests that gap junction modifier, such as Gap-134, could be an effective anti-fibrotic agent in the context of age-dependent fibrosis in progressive cardiac conduction disease." 01/01/2020 - "Furthermore, we found that Gap-134 prevented fibrosis despite the persistence of the conduction defects and the TGF-β canonical pathway activation. " 01/01/2020 - "The aim of this study was to investigate whether Gap-134 prevents Cx43 down-regulation with age and fibrosis development in Scn5a+/- mice. " 01/01/2020 - "Gap-134, a Connexin43 activator, prevents age-related development of ventricular fibrosis in Scn5a+/- mice."
3.	Temporal Lobe Epilepsy 04/15/2016 - "In the present study, we have investigated the effects of GAP-134, a recently developed specific activator of glial GJ, on both the PUI and the frequency of the 4AP-induced epileptiform activities in human neocortical slices of temporal lobe epilepsy tissue. "
4.	Atrial Fibrillation 04/01/2009 - "Effects of chronic gap junction conduction-enhancing antiarrhythmic peptide GAP-134 administration on experimental atrial fibrillation in dogs." 08/15/2009 - "In an effort to discover potent, orally bioavailable compounds for the treatment of atrial fibrillation (AF) and ventricular tachycardia (VT), we developed a class of gap-junction modifiers typified by GAP-134 (1, R(1)=OH, R(2)=NH(2)), a compound currently under clinical evaluation. " 06/01/2009 - "The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model."
5.	Ischemia 01/01/2020 - "Gap26 and GAP-134 were administered starting from 3 d post focal ischemia. " 09/01/2009 - "In dogs subjected to 60-minute ischemia and 4-hour reperfusion, GAP-134 was administered 10 minutes before reperfusion as a bolus + intravenous (IV) infusion. " 09/01/2009 - "The antiarrhythmic dipeptide, GAP-134, ([2S,4R]-1[2-aminoacetyl]-4-benzamido-pyrrolidine-2-carboxylic acid) was evaluated in canine ischemia/reperfusion model. "

Related Drugs and Biologics

1.	Connexin 43 (Connexin43)
2.	antiarrhythmic peptide (AAP)
3.	Carboxylic Acids
4.	pyrrolidine
5.	Dipeptides
6.	hydroxide ion